Vet in Athens Georgia http://TheCatandDogClinic.com
If you really love your pet you'll treat him/her like we do at The Cat and Dog Clinic in Athens Georgia. We love cats and dogs too and we take pride in giving them the very best care whether is boarding, vaccinations, emergencies... anything that requires loving care we're here for your family buddy.
The Asthma and Allergy Foundation of America (AAFA) and Teva Respiratory released results today from a new survey which showed that more than half (59 percent) of nasal allergy sufferers polled reported sleep issues as a result of their allergy symptoms, yet only 35 percent proactively treat their nasal allergy symptoms. Furthermore, nearly half of those surveyed (48 percent) said their nasal allergy symptoms, such as nasal congestion and sneezing, also interrupted their partner’s sleep.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60975-teva-respiratory-aafa-ditch-the-drip-misty-may-treanor-nasal-allergies
The number of gout patients is rising, with an estimated 8.3 million American adults diagnosed with gout—but only 10 percent of them are being properly treated, according to the Gout & Uric Acid Education Society. To heighten awareness and knowledge about gout and to lead to earlier diagnosis and treatment, the society has released two new comprehensive kits to educate patients and provide consistent information for medical professionals. The release of the Take a Stand on Gout Patient Education Kit and Medical Professional Information Kit coincides with Gout Awareness Day, an annual commemoration on May 22 to call attention to the growing incidence of gout and to enhance knowledge so as to improve patient outcomes. Both kits provide new, substantial information about gout from specialists, who treat gout patients every day.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61805-gout-uric-acid-education-society-take-a-stand-on-gout-new-information-kits
Do you really think you can hit me and put your baby in me and than just forget about me? I don't think so. I still love you. I say your name all the time over and over. Mohammad Kashif Wasi. You cannot continue to ignore me. You think I am a toy? You think because I was an office temp at Monsanto that I am your toy? I will come to Texas and we will have a life together without Samira. Just you me and the baby and I forgive you Kashif. Just treat me with respect, okay? I deserve at least that. Answer me when I call you and write to you and I won't keep having to make these desperate and pathetic videos. I hate myself right now okay look what you do to me Kashif I love you.
More than 20 million Americans are currently affected by cataracts, and a new survey from AARP Media Sales and Alcon, the global leader in eye care, found that there are many questions and misperceptions among baby boomers about the condition, their options and how to treat it.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63529-alcon-and-a-a-r-p-mark-world-sight-day-first-live-cataract-education-event
This week Hill-Rom (NYSE: HRC) is featuring the Progressa® bed system, the next generation of intensive care unit (ICU) bed systems, at the American Organization of Nurse Executives (AONE) annual meeting in Orlando, Fla. The Progressa bed system is a therapeutic system designed to treat and prevent complications of immobility. It features a state-of-the-art design that supports treatment goals and was engineered to help address patient migration via its StayInPlace™ technology.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/66137-hill-rom-new-progressa-bed-system
An iconic symbol of Easter, the PEEPS® brand has been the Easter basket staple for just over 60 years. With more than 1.5 billion PEEPS® consumed during Easter alone, it’s no wonder PEEPS® have remained the #1 non-chocolate candy at Easter for more than 20 years. From making colorful additions to baked goods, to decorative accents for craft and art projects, to fun little surprises hidden inside Easter eggs or simply savoring the sweet treat on its own, PEEPS® are sure to bring a smile to kids of all ages.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65392-just-born-easter-basket-favorite-peeps-offers-variety-for-everyone
MilkSplash™, the zero–calorie milk flavoring, is the perfect solution for parents who want their kids to drink more milk and make healthier beverage choices this summer. A gentle squeeze and simple stir can turn nutritious white milk into a delicious treat kids will love.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7141851-milksplash-from-s-and-d-beverage-innovations-makes-drinking-milk-awesome
The spring season is finally upon us and the candy connoisseurs at Just Born Quality Confections continue to whip up new PEEPS® flavors and products to fit every PEEPSONALITY®! With more than a dozen different product varieties available in numerous colors, shapes and flavors, the versatile marshmallow treat is sure to show up in Easter baskets, artwork and recipes and as always, the star of dioramas. Regardless of how they are used, the nostalgic favorite is sure to bring smiles to fans of all ages.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7404453-peeps-easter-marshmallow/
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology company, announced today the launch of its Hidden ScarTM Surgery program designed to certify surgeons and establish Centers of Excellence at major cancer centers and hospitals across the country. This innovative program will train surgeons on advanced minimally invasive and minimal access surgical approaches that deliver optimal clinical and aesthetic outcomes for patients. As part of the company’s broader women’s health initiative, Invuity is hosting a Hidden Scar Breast Cancer Surgery training course in advance of the American College of Surgeons (ACS) Clinical Congress.
Invuity aims to transform the surgical treatment of breast cancer with this advanced surgical approach for nipple sparing mastectomies and lumpectomies (breast conserving surgery). Hidden Scar Breast Cancer Surgery expands surgical options for patients, offering superior cosmetic outcomes that can improve their psychological and emotional recovery and enhance quality of life after surgery.1
With growing demand for less invasive alternatives to breast cancer surgery, surgeons need to operate through smaller incisions with limited fields of vision. Invuity’s illumination technology allows surgeons to access and visualize the entire breast cavity through discrete incision locations, enabling surgeons to safely and effectively treat breast cancer while preserving the natural shape of the breast and thereby minimizing and hiding the scars.
To view the multimedia release go to:
http://www.multivu.com/players/English/7644051-invuity-hidden-scar-breast-cancer-surgery-program/
